- Address: Hybrid: City Hall Langen (Neue Stadthalle Langen), Germany and virtual
- Organizer: Paul-Ehrlich-Institut
- Registration necessary: Yes
Gene therapy medicinal products (GTMPs) are evolving rapidly as treatment options for patients with monogeneic disorders or malignant diseases such as lymphoma and leukemia. Innovative approaches including gene editing and RNA based gene therapies will pave the way for new clinical indications, but also pose new challenges for developers and regulators.
This workshop will provide an overview of development and regulatory aspects of novel gene therapies and presents a forum for an open exchange between all stakeholders.
- Dr Brigitte Anliker
- Prof Dr Christian Buchholz
- Dr Egbert Flory
- Dr Matthias Renner
- Dr Jürgen Scherer
- Dr Martina Schüßler-Lenz
- Facilitate dialogue between developers and regulators
- Discuss new developments such as gene editing, RNA-based therapies
- Address new challenges regarding the Clinical Trials Regulation (EU) No 536/2014 and the GMO interface
- Provide insights into quality, non-clinical and clinical requirements for gene therapy development
- Developers including academia and industry (SME, biotech)
- Health Care Professionals
- GMP authorities and Regulators
- Health Technology Assessment and reimbursement bodies
- Participation in the workshop is free of charge
Details regarding the workshop programme and registration will follow soon.
Workshop is organized by the Paul-Ehrlich-Institut and will be conducted as a hybrid meeting. For more information please visit our website.